Gild articles
-
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
-
McIlrath & Eck LLC Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
McIlrath & Eck LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 67.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 550 shares of the biopharmaceutical company’s stock after buying an additional 221 shares during the quarter. McIlrath […]
-
Victory Capital Management Inc. Has $201.69 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Victory Capital Management Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,489,705 shares of the biopharmaceutical company’s stock after purchasing an additional 178,536 shares during the quarter. […]